With several additional patients anticipated to be initiated for this drug therapy, related follow-up visits over the next months at FAZiT will be included in further study analyses. Conclusion: These first data suggest that oral chaperone therapy in Fabry disease can be a well-tolerated feasible alternative to enzyme replacement therapy in Fabry disease. In addition to direct therapeutic effects, patients with amenable α-galactosidase A gene mutations potentially benefit through increased quality of life by oral therapy instead of biweekly intravenous therapy. Prompt versus delayed initiation of agalsidase alfa enzyme replacement therapy (ERT) following diagnosis or symptom onset of Fabry disease (FD) has been shown to be beneficial using data from the Fabry Outcome Survey (FOS; sponsored by Shire). This post-hoc analysis used data from FOS patients with available date of symptom onset or diagnosis of FD and treatment start date. Cardiovascular outcomes included myocardial infarction, left ventricular hypertrophy, and heart failure. Time to first cardiovascular event was compared between prompt (<24 months) vs. delayed (≥24 months from FD symptom onset or diagnosis) ERT initiation from the start of therapy until 96 (symptom onset) or 120 (diagnosis) months. Kaplan-Meier curves of the groups were compared using a log rank test. Cox regression using age at time of diagnosis as a covariate was used to estimate hazard ratios (HR) between groups. These analyses included 1275 patients (147 prompt, 1128 delayed; males 804, females 471) based on time from symptom onset and 1759 (854 prompt, 905 delayed; males 1045, females 714) based on time from diagnosis. In the overall population, prompt ERT initiation was associated with significant benefits in the reduction of time to cardiovascular events: both since symptom onset (HR=0.449; log-rank p<0.0001) and since diagnosis (HR=0.770; log-rank p<0.0006; Figure) . Analysis by sex showed that these benefits were seen in both male (symptom HR=0.559, p=0.0171; diagnosis HR=0.784, p=0.0120) and female (symptom HR=0.267, p=0.0003; diagnosis HR=0.775, p=0.0415) patients. Analysis by age at symptom onset showed that the beneficial effect of prompt initiation was more profound in patients ≤20 years of age at symptom onset. Prompt initiation of agalsidase alfa ERT (within 24 months) was associated with significantly better cardiovascular outcomes vs. delayed initiation of ERT (more than 24 months after symptom onset or diagnosis of FD), independent of sex. Age at symptom onset may be an important contributing factor. Background: Fabry disease is an X-chromosomal inherited multisystem disease that can cause numerous organ involvements. In addition to the involvement of the heart with progressive hypertrophy and fibrosis ultimately leading to the development of progressive heart failure and malign arrhythmia, damage to the nervous system and the kidneys is also clinically relevant. In the currently valid therapeutic recommendations, the efficacy of enzyme replacement therapy in patients with advanced organ involvement is assessed unfavorably and consequently is controversially evaluated or no longer recommended at a GFR <60 (<45) ml/min/1.73 m 2 (recommendation class IIb/III), as well as in advanced myocardial fibrosis. Objective: To evaluate the efficacy of an enzyme therapy through a retrospective monocentric analysis of patients with a GFR <60 ml/min/1.73 m 2 , before start of therapy.
Prompt versus delayed initiation of agalsidase alfa enzyme replacement therapy (ERT) following diagnosis or symptom onset of Fabry disease (FD) has been shown to be beneficial using data from the Fabry Outcome Survey (FOS; sponsored by Shire). This post-hoc analysis used data from FOS patients with available date of symptom onset or diagnosis of FD and treatment start date. Cardiovascular outcomes included myocardial infarction, left ventricular hypertrophy, and heart failure. Time to first cardiovascular event was compared between prompt (<24 months) vs. delayed (≥24 months from FD symptom onset or diagnosis) ERT initiation from the start of therapy until 96 (symptom onset) or 120 (diagnosis) months. Kaplan-Meier curves of the groups were compared using a log rank test. Cox regression using age at time of diagnosis as a covariate was used to estimate hazard ratios (HR) between groups. These analyses included 1275 patients (147 prompt, 1128 delayed; males 804, females 471) based on time from symptom onset and 1759 (854 prompt, 905 delayed; males 1045, females 714) based on time from diagnosis. In the overall population, prompt ERT initiation was associated with significant benefits in the reduction of time to cardiovascular events: both since symptom onset (HR=0.449; log-rank p<0.0001) and since diagnosis (HR=0.770; log-rank p<0.0006; Figure) . Analysis by sex showed that these benefits were seen in both male (symptom HR=0.559, p=0.0171; diagnosis HR=0.784, p=0.0120) and female (symptom HR=0.267, p=0.0003; diagnosis HR=0.775, p=0.0415) patients. Analysis by age at symptom onset showed that the beneficial effect of prompt initiation was more profound in patients ≤20 years of age at symptom onset. Prompt initiation of agalsidase alfa ERT (within 24 months) was associated with significantly better cardiovascular outcomes vs. delayed initiation of ERT (more than 24 months after symptom onset or diagnosis of FD), independent of sex. Age at symptom onset may be an important contributing factor. Background: Fabry disease is an X-chromosomal inherited multisystem disease that can cause numerous organ involvements. In addition to the involvement of the heart with progressive hypertrophy and fibrosis ultimately leading to the development of progressive heart failure and malign arrhythmia, damage to the nervous system and the kidneys is also clinically relevant. In the currently valid therapeutic recommendations, the efficacy of enzyme replacement therapy in patients with advanced organ involvement is assessed unfavorably and consequently is controversially evaluated or no longer recommended at a GFR <60 (<45) ml/min/1.73 m 2 (recommendation class IIb/III), as well as in advanced myocardial fibrosis. Objective: To evaluate the efficacy of an enzyme therapy through a retrospective monocentric analysis of patients with a GFR <60 ml/min/1.73 m 2 , before start of therapy.
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Methods and results:
From the 272 patients with Fabry disease treated in the Fabry Center for Interdisciplinary Therapy (FAZiT), those with a GFR <60 ml/min/1.73 m 2 before start of therapy were included in the analysis (mean age at start of therapy 52.2±13 years, total range 38-71 years). In all patients, annual follow-up visits were performed including an inspection of GFR (MDRD) and serum creatinine (mg/dl). Patients received Agalsidase α or β, endpoints were the onset of hemodialysis or death due to cardiac or other cause. After grade of renal function loss, two subgroups (GFR (MDRD) 45-60 ml/min/1.73 m 2 as well as GFR (MDRD) <45 ml/min/1.73 m 2 ) were formed. Patients from the first subgroup showed a decrease in the glomerular filtration rate of 9.22±14% with an increase in creatinine of 10.4±17% within the first year. The second subgroup showed a decrease in GFR of 5.2±14% with a creatinine increase of 6.25±12%. With a reduction in renal function by 10.34±20% (GFR 45-60 ml/min/1.73 m 2 ) or by 10.94±28% (GFR <45 ml/min/1.73 m 2 ) in a time period of 2.4±0.8 years, no difference could be found in comparison with results in published literature that included patients with an earlier start of therapy. The longest observation period in the investigated cohort was 10 years. In this subgroup, the GFR decreased from 52 to 25 ml/min/1.73 m 2 . This matches with an average annual decrease of 2.7 ml/min/1.73 m 2 . None of the endpoints were reached. Conclusion: The data suggest that enzyme replacement therapy in Fabry disease shows positive effects even if advanced organ function impairments are already present in advanced stages of this disease. On this occasion, the general recommendation for the earliest possible start of a causal therapy to prevent any organ damage in predisposed patients remains unaffected. Introduction: Fabry disease is an X-linked hereditary disorder due to the lack of the alpha-galactosidase activity leading to the cardiac involvement such as left ventricular hypertrophy (LVH). The enzyme replacement therapy (ERT) is a promising treatment to prevent serious complications. However, the long-term effect of ERT on LVH in Japanese Fabry patients has not been investigated. Purpose: We investigated the prevalence of left ventricular hypertrophy (LVH) and the long-term effect of enzyme replacement therapy on LVH in Japanese Fabry patients. Methods: We retrospectively analyzed echocardiographic parameters from medical records of 17 male (median 11 years) and 25 female (median 8 years) patients followed in our University hospital. Results: The prevalence of LVH was higher and younger in male patients. Left ventricular mass index (LVMI) was significantly larger in male and strongly correlated with age. The slope of LVMI increase (mean ± SEM) was 1.25±0.34 g/m 2.7 /year in male and was 0.78±0.25 g/m 2.7 /year in female, which were significantly smaller than the values reported without ERT (4.07±1.03 g/m 2.7 /year in male and 2.31±0.81 g/m 2.7 /year in female, p<0.05). In subgroup analysis, there were no statistical differences in the slope between male with and without LVH. However, the slope was significantly smaller in the patients without LVH than those with LVH in female patients (p<0.05) (figure).
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